Advanced Life Sciences Inc. (ADLS) is an emerging pharmaceutical company focused on the development and commercialization of novel drugs for the treatment of infectious disease, oncology and respiratory disorders. Its lead drug candidate Cethromycin, which is developed for the treatment of acquired pneumonia, cleared phase III clinical trials. In addition, the Company maintains licensing agreements with Abbott Laboratories for worldwide commercialization and further development of Cethromycin. The Company also has a portfolio of drug therapies candidates under preclinical trials, including ALS-357 to treat melanoma, and ALS-886 to treat acute respiratory distress.

Founded in 1999, the Company is headquartered in Woodridge, Illinois.

Source: Reuters.com, SEC Filings.

ADLS is an emerging pharmaceutical company in infancy, with little to no revenue at its early stage of development.

Operating expenses for the first quarter of fiscal 2009 totaled $2.4 million, down from $3.6 million for the same quarter of fiscal 2008. The Company cites tighter cost controls and lowered research and development of its lead product, Cethromycin. The Company posted a loss for the most recent quarter of $2.3 million, or 5.6 cents per share, smaller than the loss of $3.5 million, or 9.3 cents per share, reported for the first quarter of fiscal 2008.

At the close of the quarter ended March 31, cash/cash equivalents totaled $0.5 million. Cash burned in the quarter totaled $1.6 million.

To fund ongoing operations through 2009, the Company anticipates raising additional capital through commercial partnerships and/or the sale of equity.

Source: Reuters.com

The Company is not covered by any major equities research firm at this stage of development.

ADLS is an emerging pharmaceutical Company focused on development and commercialization of novel drugs for the treatment of infectious disease, oncology and respiratory disorders. Its lead drug candidate Cethromycin, which is developed for the treatment of acquired pneumonia, has cleared phase III clinical trials.

Following rapid growth rates from 2004 to 2008, drug sales of respiratory related conditions is expected to reach $23 billion by 2018, according to The Datamonitor Group, while the most recent statistics for the global market potential of the Company’s ALS-357 anti-cancer drug therapy could reach approximately $53 billion for 2009.

If approved by the U.S. Food and Drug Administration (FDA), the market for ADLS’ drug candidate Cethromycin could reach more than $1 billion at its market saturation. Cethromycin has cleared phase III clinical trials, with the prospects of reaching commercialization reaching approximately 90% following final approval from the FDA.

Pharmaceutical companies with revenue of more than $1 billion but less than $2 billion include Cephalon, Inc. (Nasdaq: CEPH), which trades at a market capitalization of $3.73 billion, and King Pharmaceuticals (Nasdaq: KG), which trades at a market capitalization of $2.25 billion. ADLS trades at a market capitalization of $29.9 million.

On June 23, 2009, the Company announced the results of a second study regarding its lead drug candidate Cethromycin, showing a 100% survival rate of non-humans that inhaled lethal dosages of anthrax. No animals receiving a placebo survived. The study was confirmed by the National Institute of Allergy and Infectious Diseases (NIAID), a branch within the Health and Human Services (HIS) Agency of the United States government.

On June 19, 2009, ADLS filed a Form 8-K with the Securities and Exchange Commission (SEC), which states that the Company has entered into an Equity Distribution Agreement (the “New SEDA”) with YA Global Master SPV Ltd. (“YA SPV”) for the sale of up to $15.0 million of shares of common stock over the next two years.

Source: http://stockcharts.com/h-sc/ui

ADLS trades above its 13-day moving average. This bullish sign is more significant because the moving average is beginning to also trend higher.

The MACD for ADLS currently indicates a bullish signal. The MACD is above the signal line, a 9-day moving average; but the MACD is, however, below the critical level of 0, which implies that the underlying moving averages had been trending lower. Overall, the chart is slightly bullish.

The Company is traded with premium to peer group P/S multiples, mainly due to its potential and speculation of FDA approval of its lead drug candidate Cethromycin. The Company is in development stage.

Source: Thomson Financial

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

• Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
• See today’s top stock picks and market analysis
• Want more? Check out the message board buzz for these stocks
• See what newsletters are recommending these stock picks
• Get breaking news alerts on these stocks: http://thestockmarketwatch.com/
• This newsletter has been helping traders make a killing on these stocks. Click here for a 25% discount offer.

About BeaconEquity.com

BeaconEquity.com is committed to producing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily OTC stocks in the stock market today, which have traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.

Beacon Equity Group Disclaimer

This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Beaconequity.com is a wholly-owned subsidiary of BlueWave Advisors.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.